Linking biotech and investors: Stellar AusBioInvest 2022 programme launched


The programme for Australia’s largest life sciences investment conference, AusBioInvest 2022, has launched.

The programme engages capital with health innovation. It features global and local keynotes and panellists sharing insights to support informed investment decisions in a complex scientific field, and up to 30 public and private Australian biotechnology company presentations.

Australia’s pre-eminent life science investment event offers the opportunity for potential partners and investors, including global pharma representatives, to engage with Australia’s world-leading biotech companies as they present the latest, detailed information about their business case and technologies.

The event draws key decision makers from the investment community, including venture capitalists, private equity firms and investment bankers; as well as research analysts and representatives from pharmaceutical companies, and from governments. The event merges market intelligence with investment opportunities and acts as a guide to successful biotech investment. 

The Hon Roger Cook MLA, Deputy Premier; Minister for State Development, Jobs and Trade; Tourism; Commerce; Science, Government of Western Australia will join AusBiotech CEO Lorraine Chiroiu for the event’s Welcome to Country and official opening, before the one-day programme focuses on why access to capital remains key amid biotech’s expanding industry.

Keynotes presentations include:

  • Inside the mind of a venture capitalist: how to build an innovative biotech company, Dr Nilay Thakar, Principal, ARCH Venture Partners, United States- one of the most respected and largest, most active and successful, VC funds in biotech - clinically and financially;
  • Global trends in biotech and healthcare: leveraging US and Australian opportunities, Dr Daniel Getts, CEO and Co-Founder, Myeloid Therapeutics, United States;
  • ASX Market Update on opportunities and headwinds for Australian life sciences, James Posnett, General Manager Listings, ASX Limited; and,
  • Translating ground-breaking science into new medicines in the 21st Century: A VC’s perspective, Dr Arjun Goyal, Co-Founder and Managing Director, Vida Ventures, United States a leading US-based life sciences venture capital firm with approximately US$1.7 billion in assets under management.

These presentations will be complemented with expert panel discussions on: Investor insights: New funds, emerging funding models and avenues for capital; and International investors unplugged, and includes heavy-weight investors such as Executive Chair Dr. Steve Burnell from Australia’s newest $250M healthtech investment fund Tenmile, backed by Tattarang - one of the largest diversified private investment groups in Australia that's owned by Andrew and Nicola Forrest.

Up to 30 C-suite of innovative biotech companies will present, including: Patrys (ASX:PAB), Prescient Therapeutics (ASX:PXT), Invion (ASX:IVX), Dimerix (ASX:DXB), Argenica Therapeutics (ASX:AGN), Emyria Limited (ASX:EMD), Orthocell Ltd (ASX:OCC), Noxopharm Limited (ASX:NOX), LBT Innovations (ASX:LBT), Microba (ASX:MPA), Immuron (ASX:IMC), Opyl (ASX:OPL), Living Cell Technologies (ASX:LCT), INOVIQ (ASX:IIQ), Carina Biotech, Cerecin, Tessara Therapeutics, FivepHusion, HaemaLogiX, Celosia Therapeutics, EpiAxis Therapeutics, Carpe Vitae Pharmaceuticals and Respirion Pharmaceuticals.

This premier event will lift the profile of the Australian biotechnology industry and create access to greater funding sources for local companies to develop world-class science into therapies, diagnostics and medical devices.  

Download the AusBioInvest 2022 programme here, and register for the event here.

AusBioInvest 2022 is proudly sponsored by the WA Government and Business Events Perth.